WO2003002730A2 - Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode - Google Patents
Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode Download PDFInfo
- Publication number
- WO2003002730A2 WO2003002730A2 PCT/FR2002/002178 FR0202178W WO03002730A2 WO 2003002730 A2 WO2003002730 A2 WO 2003002730A2 FR 0202178 W FR0202178 W FR 0202178W WO 03002730 A2 WO03002730 A2 WO 03002730A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calpaine
- peptide
- isoform
- calpain
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 92
- 108030001375 Calpain-3 Proteins 0.000 title claims abstract description 58
- 230000000694 effects Effects 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 48
- 239000012472 biological sample Substances 0.000 title claims abstract description 24
- 102000046744 Calpain-3 Human genes 0.000 title claims abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 23
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 239000000284 extract Substances 0.000 claims description 36
- 102000001708 Protein Isoforms Human genes 0.000 claims description 34
- 108010029485 Protein Isoforms Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 208000035404 Autolysis Diseases 0.000 claims description 30
- 206010057248 Cell death Diseases 0.000 claims description 30
- 238000003776 cleavage reaction Methods 0.000 claims description 30
- 230000007017 scission Effects 0.000 claims description 30
- 230000028043 self proteolysis Effects 0.000 claims description 30
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 22
- 230000003213 activating effect Effects 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 101150090724 3 gene Proteins 0.000 claims description 5
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 208000037148 Calpain-3-related limb-girdle muscular dystrophy R1 Diseases 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102100032539 Calpain-3 Human genes 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 29
- 239000013612 plasmid Substances 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 108010032088 Calpain Proteins 0.000 description 14
- 102000007590 Calpain Human genes 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000002950 deficient Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 210000003098 myoblast Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010002947 Connectin Proteins 0.000 description 2
- 102000004726 Connectin Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002358 autolytic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- -1 calcium-activated cysteine Chemical class 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000001964 muscle biopsy Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OTMNDJSZWCOSAK-UHFFFAOYSA-N 1-n'-naphthalen-1-ylethane-1,1-diamine Chemical group C1=CC=C2C(NC(N)C)=CC=CC2=C1 OTMNDJSZWCOSAK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000003895 Calpain-1 Human genes 0.000 description 1
- 108090000236 Calpain-1 Proteins 0.000 description 1
- 102000003900 Calpain-2 Human genes 0.000 description 1
- 108090000232 Calpain-2 Proteins 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010031746 Dam methyltransferase Proteins 0.000 description 1
- 101000621107 Enterobacteria phage N4 Probable portal protein Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 101001019513 Homo sapiens Calpastatin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001019506 Mus musculus Calpastatin Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101000599850 Rattus norvegicus Calpastatin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000045597 human CAST Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the invention relates to a method for detecting the activity of calpaine 3 in a biological sample consisting of either cells, cell lines or tissues. It also relates to the peptides intended to be used in said method. The invention also relates to the use of said peptides for the in vitro diagnosis of dystrophy of type 2A belts (LGMD 2A). It also relates to a method for analyzing the efficiency of the transfer of the calpaine 3 gene in animal or human cells in vitro but also in animals in vivo. It also relates to a method of screening for inhibiting or activating substances of calpain 3. The method of detecting the activity of calpaine 3 finally constitutes a means of studying the function of calpaine 3.
- Calpains are a family of non-lysosomal calcium-activated cysteine proteases [Sorimachi, 1997]. This family currently includes 11 members including 2 ubiquitous proteins. The physiological functions of calpains are still largely unknown. As regulatory proteases, they are likely to regulate important cellular functions. In particular, ubiquitous calpains have been implicated in apoptosis [Squier, 1994], myogenic differentiation [Kwak, 1993], cell division and fusion [Yamaguchi, 1994]; [Schollmeyer, 1986]; [Balcerzak, 1995].
- Calpaine 3 also known under the name p94, is a calcium cysteine-dependent enzyme belonging to the calpain family expressing itself specifically in skeletal muscle [Sorimachi, 1989]. She is involved in an autosomal recessive genetic disorder called type 2A belt dystrophy [Richard, 1995]. This myopathy is characterized by atrophy and progressive weakness of the muscles of the pelvic and shoulder girdles and an aspect of necrosis regeneration on muscle biopsies [Fardeau, 1996]. The gene located on chromosome 15 in humans codes for a 3.5kb transcript, itself coding for a 94kDa protein.
- LGMD2A is due to mutations appearing on the calpain 3 gene, mutations leading to an inhibition of the proteolysis of calpaine 3 present in skeletal muscle.
- the clinical diagnosis of LGMD 2 A is very difficult since patients present clinical signs similar to at least ten other pathologies. Molecular diagnosis can be carried out using different methods.
- the first possibility is to search for a mutation on the calpain gene.
- search for a mutation on the calpain gene is very cumbersome insofar as the gene is relatively large, that there are therefore a large number of different mutations and that there is no preferential mutation.
- Another technique is to detect the presence of the protein using specific antibodies.
- calpaine 3 is present in the sample, this does not mean that the individual is not sick since the mutation on the calpaine gene can make the protein present but that the autolysis phenomenon does not exist.
- the calpain is absent or diminished, it may be a secondary calpainopathy due to mutations on a gene other than that of calpain.
- the problem which the invention proposes to solve is not so much to detect the presence of calpaine 3 in a biological sample but rather that of detecting its activity.
- the problem which the invention proposes to solve is to develop a new specific substrate for calpain 3 which can be used to detect the activity of calpaine 3 in a biological sample.
- the invention relates first of all to a peptide coupled to at least one fluorogenic or colorogenic reporter molecule, said peptide being characterized in that it contains at least one amino acid sequence capable of being cleaved by calpain 3 or an isoform of calpain 3.
- the peptide of the invention advantageously contains at least one autolysis site of calpaine 3 or of an isoform of calpaine 3, the number of which d amino acids is less than 10.
- autolysis site denotes an amino acid sequence contained in calpaine 3 or one of its isoforms capable of being cleaved by calpaine 3 or one of its isoforms in at least two peptides as well as any derived sequence.
- amino acid sequence of the autolysis site of calpaine 3 is chosen from the following sequences NMTYGTS (SEQ ID1), NMDNSLL (SEQ ID2), PVQYETR (SEQ ID3) called in the following description respectively site 1, site 2 and site 3. These sites are identical in all the species for which the sequence of calpaine 3 is known to date (man, mouse, rat,).
- the amino acid sequence of the calpain 3 autolysis site can also be chosen from the following human sequences VAPRTA AEPRSP (SEQ ID4), QSKATE AGGGNP (SEQ LD5), and the following murine sequences NAPRTG AEPRSP (SEQ ID6), QGKTTE AGGGHP (SEQ ID7).
- the amino acid sequence of the autolysis site comes from an isoform of calpaine 3 called Lp82 present in rodents, rats, mice and is chosen from the following amino acid sequences: ⁇ PYLLPGFFC (SEQ ID8) and TISNDRPVP (SEQ ID9).
- the substrate proteins have the following sequences:
- REVTIPP YRELL (SEQ LD10) (human calpastatin)
- KEGTIPPEYRKLL (SEQ ID11) (mouse and rat calpastatin)
- PVSREEKPTSAPSS (SEQ ID12) (human alpha-A-crystalline)
- PVSREEKPSSAPSS (SEQ ID13) (alpha-A-crystalline mouse and rat)
- KSTNLQQQYNR SEQ ID14
- the peptide containing a sequence cleavable by calpaine 3 or an isoform of calpaine 3, is obtained by screening a library of peptides by calpaine 3 or an isoform of calpaine 3.
- the peptide of the invention is coupled to a colorogenic or fluorogenic reporter molecule.
- the reporter molecule When the reporter molecule is a colorogenic molecule, the cleavage of the amino acid sequence by calpaine 3 will be detected with a spectrophotometer by the appearance of a colored compound.
- the colored compound used is paranitroanilide. It can also be thioesters.
- the cleavage is detected by a change in the fluorescent emission.
- the fluorogenic compound used is methyl 4 coumarilamide 7 (MCA) or naphthilamide.
- MCA methyl 4 coumarilamide 7
- Naphthilamide and amino 7 fluoromethylcoumarylamide 3 can be used as a colorogenic or fluorogenic substrate.
- the peptide cleavable by calpaine 3 is coupled at its two ends by two fluorogenic compounds, the cleavage being detected by a change in the fluorescent emission of a first compound (donor molecule) due to the distancing, secondarily upon cutting, of a second compound (acceptor molecule) located on the other side of the peptide and which absorbs the fluorescence of the first when these are close.
- FRET Fluorescence Resonance Energy Transfer
- FRET is a physical phenomenon which can occur between two fluorescent molecules under certain conditions: the two molecules must be close enough to each other (less than 100 ⁇ ) and the emission spectrum of one of the molecules (the donor molecule) must cover the excitation spectrum of the second molecule (the acceptor molecule).
- the donor molecule when the donor molecule is excited at its excitation wavelength, it reaches a higher energy level. In a few picoseconds, part of the energy is dispersed in the medium in different forms (heat ). If the donor molecule is in an optimal orientation and close to an acceptor molecule, its energy can be transferred to this acceptor molecule without the intervention of a photon or the need for collision between the two molecules.
- the acceptor molecule is then excited and emits light at its own emission wavelength.
- the fluorogenic reporter molecule can be a synthetic molecule obtained by chemical synthesis or a protein allowing the emission of a fluorescent signal.
- the peptide has at each of its ends a synthetic fluorogenic reporter molecule, respectively MCA (donor molecule) and Dnp (acceptor molecule).
- the donor is 5 - [(2 'aminoethyl) - amino] naphthalene sulfonic acid (EDANS) and the acceptor is 4 - [[4' - (dimethyl amino] phenyl] acid) azo] benzoic (DABCYL).
- the peptide of the invention coupled to the colorogenic or fluorogenic molecule is obtained by chemical synthesis.
- the reporter molecule can also be a protein allowing the emission of a fluorescence signal. Therefore and in an advantageous embodiment, the peptide has at each of its ends a mutated GFP.
- CFP When these two proteins are close enough to each other and when CFP is excited at its excitation wavelength, CFP can transfer its activation energy to YFP which can then emit light at 535 nm.
- the sequences corresponding to the previously mentioned calpain 3 autolysis sites will therefore be cloned between the CFP and YFP sequences.
- This system will be used to detect calpaine 3 by producing in living cells chimeric proteins within which CFP will be linked to YFP by a peptide cleavable by calpaine 3.
- the invention also relates to a DNA sequence coding for a peptide coupled to at least one fluorescent protein, said peptide containing at least one amino acid sequence capable of being cleaved by calpain 3 or an isoform of calpam 3.
- the DNA sequence codes for the following peptides: CFP-site 1- YFP; CFP-site 2- YFP; CFP-site 3- YFP
- the invention also relates to a vector containing said DNA sequence and a promoter for inducing expression of the DNA sequence in a host cell.
- a vector is for example the plasmid pTOM developed by the Applicant, directly derived from the plasmid described in [Nanderklish 2000]. It also relates to a host cell transformed by said vector.
- the invention also relates to a method for in vitro detection of the activity of calpaine 3 or of an isoform of calpaine 3 in a biological sample according to which: in a first step, said biological sample is brought into contact with the peptide previously described, in a second step, the presence or absence of cleavage of said peptide by calpaine 3 or an isoform of calpaine 3 is detected by measuring the intensity of the colorimetric or fluorimetric reaction.
- the first step can take different forms depending on whether the detection is carried out on a biological sample consisting of either living cells or a cell extract, the cells being of animal or human origin, or of tissue.
- contact with the peptide can be done in two ways.
- the peptide is brought directly into contact with the cell so that it must have sufficient permeability properties to penetrate the cell.
- the permeability of the peptide will be determined according to the nature of the reporter molecule.
- the biological sample corresponds to host cells transfected with a vector coding for the DNA sequence corresponding to the peptide of the invention, the reporter molecules then corresponding to proteins allowing the emission of a fluorescent signal.
- the peptide is simply brought into contact with said extract.
- the detection of the activity can also be done, as already said, directly on tissue sections.
- the biological sample organ, part of an organ, for example muscle biopsies
- isopentane cooled with liquid nitrogen. It is stored at -80 ° C until use.
- Sections from 5 to 15 ⁇ m are made using a cryostat and placed on a glass slide.
- the sections are also stored at -80 ° C if they are not used immediately.
- the detection of calpain activity can be carried out by depositing the peptide directly on the slide.
- the peptide has, at each of its ends, respectively a donor fluorogenic molecule and an acceptor fluorogenic molecule, the intensity of the fluorogenic reaction being determined by FRET.
- FRET fluorogenic reaction
- the method for detecting the activity of calpaine 3 or of an isoform of calpaine 3 finds an advantageous application for the in vitro diagnosis of
- LGMD2A Consequently, the invention also relates to the use of the detection method described above for the in vitro diagnosis of LGMD2A.
- the invention also relates to a method for screening for inhibiting or activating substances of calpain 3 or of an isoform of calpaine 3.
- Said method can take two different embodiments. According to a first embodiment, the method consists:
- the biological sample can be in the form of cells, cellular extracts or even tissues.
- the preparation of the biological sample containing the peptide is then carried out by mixing the treated sample (cell, cell or tissue extract) with the peptide.
- the peptide has, at each of its ends, respectively a donor fluorogenic molecule and an acceptor fluorogenic molecule, the intensity of the fluorogenic reaction being determined by FRET.
- the method consists:
- the biological sample consists of cells or cell lines transfected with a vector comprising the DNA sequence coding for the peptide of the invention, in the event that the reporter molecule is of protein origin.
- the peptide has at each of its ends respectively a donor fluorogenic molecule and an acceptor fluorogenic molecule and the method consists in: a / preparing a biological sample containing said peptide, b / measuring the FRET level in l absence of the activator or inhibitor substance of calpain 3 or of a calpain 3 isoform, c / bringing the biological sample containing the peptide into contact with the activating or inhibiting substance of calpaine 3 or of an isoform of calpaine 3, d / measuring the FRET level in the presence of the activating or inhibiting substance of calpaine 3 or an isoform of calpain 3, e / conclude that there is: an activating substance if the FRET level measured in b / is greater than the FRET level measured in d / an inhibiting substance if the rate FREIGHT measured in b / is equal to the FRET rate measured in d /
- the subject of the invention is also a method of analyzing the efficiency of the gene transfer from calpaine 3 consisting of:
- the peptide has, at each of its ends, respectively a donor fluorogenic molecule and an acceptor fluorogenic molecule, the intensity of the fluorogenic reaction being determined by FRET.
- the calpaine 3 gene is perfectly identified and the transfection techniques precisely described in document EP 717110 so that they will not be further detailed.
- Figure 1 Partial sequence of calpaine 3; the position of the autolysis sites is indicated by the arrows; the sequences used in the peptides are underlined and are identical in all the species for which the sequence of calpain 3 is known to date (man, mouse, monkey, rat, ox).
- Figure 2 Measurement over time of the cleavage activity of the peptides corresponding to the autolysis site 1, 2 and 3 of calpain 3 (curves A, B and C, respectively) by calpains 1 (left column) and 2 (right column) recombinant
- Figure 3 Measurement over time of the cleavage activity of the peptides corresponding to the autolysis sites of calpain 3 with extracts of C2C12 cells transfected or not with a plasmid coding for calpain 3.
- Figure 4 Measurement during of the time of the cleavage activity of the peptides corresponding to the autolysis sites of calpain 3 by extracts of myoblasts of normal (+ / +) or deficient in calpain 3 (- / -) mice.
- Figure 5 Measurement over time of the cleavage activity of the peptide corresponding to the site 3 of autolysis of calpain 3 by extracts of normal myotubes from mice (+ / +) or deficient in calpain 3 (- / -)
- Figure 6 Measurement for 6 hours of the cleavage activity of the peptides corresponding to the autolysis sites of calpain 3 by extracts of normal myoblasts from mice (+ / +) or deficient in calpain 3 (- / -)
- Figure 7 Measurement for 6 hours of the cleavage activity of the peptides corresponding to the autolysis sites of calpain 3 by extracts of normal mouse quadriceps (+ / +) or calpain-3 deficient (- / -)
- Figure 8 portion of sequence of the plasmid pTOM.
- the amino acids in italics are part of the EYFP sequence.
- the amino acids in fat are part of that of ECFP.
- the STOP codon of EYFP was eliminated in the vector pTOM.
- the bases in italics and in bold show the phases of the EYFP and ECFP sequences, respectively.
- the underlined bases correspond to the fragment which was eliminated to construct the vector pTOMp.
- sequences A and B correspond to the translation of the vector pTOM from the ATG of the coding sequence of EYFP, respectively before and after elimination of the double-stranded fragment located between the sites restriction Ee / 136II and Smal.
- sequence A the sequences coding for ⁇ YFP and ⁇ CFP are not in phase. They are in sequence B.
- Figure 9 A: Migration on agarose gel of the PCR products on colonies subcultured after transformation with pTOMp. The PCRs were carried out with the oligonucleotides midEYFP.a and midECFP.m. B: Migration of these PCR products after digestion with EcoRI; Well n ° l: scale lkb; # 2: pTOM; n ° 3: pTOM after digestion with Ec ⁇ RI; n ° 4 to n ° 9: migration of the PCR products from gel A after digestion with Ec ⁇ RI; their size is always 800bp.
- Figure 10 cloning site on the vector pTOM (10a) and sequence of the oligonucleotides coding for the autolysis sites of calpain 3 (10b, 10c, 10d).
- Each pair of complementary oligonucleotides is composed of an oligonucleotide whose name ends in ".a" and an oligonucleotide whose name ends in
- Figure 11 Migration on agarose gel of PCR products on colonies subcultured after transformation with pTOM and the insert coding for site 2 of autolysis; the PCR was carried out with the oligonucleotides SGp94S2.a and midECFP.m.
- Figure 12 restriction map of the plasmid pTOM
- FIG. 13 restriction map of the plasmid pTOMs1, pTOMs2, TOMs3
- Mca-NMDNSLL-Dnp site 2
- Mca-PVQYETR-Dnp site 3
- calpain 2 Rat, recombinant, E.coli (Calbiochem) caspase 3: Human, recombinant, E.coli (Calbiochem)
- the reaction is carried out at 37 ° C., either over one hour (with a fluorescence measurement every 50 seconds in this case) or over 6 hours (measurement every 2 minutes).
- the medium is agitated between each measurement.
- the wavelengths used for the detection of the fluorescence of the peptides are: - Mca excitation wavelength: 325nm.
- the reaction conditions were developed, and in particular the composition of the reaction buffer. Indeed, the detection of fluorescence has proven to be very sensitive.
- the first tests consisted in varying the different components of the buffer and their concentration. Different NaCl concentrations have been tested. The importance of a low concentration of DMSO, in which the peptides are resuspended, has been demonstrated. It has also been shown that the presence of CHAPS in the reaction medium, as well as BSA, allows optimal detection of fluorescence.
- the reactions are carried out at 37 ° C., in the presence of 10 mM of calcium. Indeed, calpaine 3 is active when it is in the presence of calcium concentrations of the order of nanomolar. Buffer composition:
- TrisHCl 50mM, Bmercaptoethanol 5mM, glycerol 40%, pH 7.8. Storage at room temperature. Fluorescent peptide resuspension buffer: The peptides are resuspended at 1 mg / ml in 100% DMSO>. Storage at 4 ° C, protected from light.
- DMEM Eagle medium modified by Dulbecco (Gibco BRL)
- MEM Non-essential amino acid solution
- SVF Fetal calf serum
- C2C12 DMEM + 10% SVF
- Plasmids used pECFP-Nl (Clontech); pEYFP-Cl (Clontech). Methods: 1 st day:
- FUGENE 6 is to be expected (cell control), as well as a well in which the cells will have been in contact with FUGENE 6 only (FUGENE 6 toxicity control).
- PB S Distrachloro phosphate-buffered solution (without calcium, magnesium or sodium bicarbonate) -
- calpain 3 has greater stability in muscle cells due to the presence of titin. In order to prove that calpain 3 could cleave its own autolysis sites, it is therefore overexpressed in C2C12 cells by transfecting these cells with a plasmid coding for calpam 3. A control transfection with pECFP was carried out at the same time than transfection with the plasmid coding for calpam 3. The transfection efficiency on C2C12 is less than 10%>. The proteins are then extracted and their activity is tested at the autolysis sites ( Figure 3).
- the curves representing the activity of transfected or non-transfected C2C12 extracts at sites 1 and 2 show a slight increase in fluorescence, which could mean that calpain 3 can cleave these sites.
- Calpain 3 is a protein expressed in muscle, therefore the basal activity observed for extracts from non-transfected cells is normal. However, no difference can be detected between transfected or non-transfected cells for sites 1 and 2.
- site 3 the cleavage activity is greater in the transfected cells. The difference is minimal but it is consistent with the small percentage of cells transfected.
- the cleavage activity on sites 1 and 2 is greater in extracts of cells + / + than in extracts of cells - / -.
- the increase in activity on site 3 is here confirmed when the reaction takes place over 6 hours.
- the activity is greater in cell extracts - / - than in cell extracts + / +.
- Oligonucleotides site 1, site 2, site 3
- SCSI 10 dam-Str R bacteria (Stratagene); XLl-Blue (Stratagene).
- Plasmid vector pTOM (Genethon) ( Figure 12).
- the complementary single-stranded oligonucleotides are brought into contact with one another at a concentration of 20 ng / ⁇ l final each in the SYBR Green buffer.
- the vector pTOM is digested with the two enzymes BamHlet BspEl at 37 ° C. for 2 h for each enzyme.
- Ligation of the oligonucleotides in pTOM In the ligation mixture, the ratio between the quantity of insert and the quantity of vector is 3 (in moles). The ligation reaction is carried out in the presence of T4 DNA ligase (BioLabs) overnight at 16 ° C.
- Electroporation conditions 2500 V, 200 ohm, 25 ⁇ F.
- the colonies are counted and subcultured in a 96-well plate in 100 ⁇ l LB + kanamycin at 10 ⁇ g / ml final. To verify the presence of the plasmid in the colonies. PCR is carried out on these colonies with either the midEYFP.a and midECFP.m pair, or the pair formed by one of the following forward oligos:
- Each oligonucleotide is SG P 94S1.
- E has CCGGAAGTGGCACGAACATG for site 1 specific for a fragment
- SGp94S2 a CCGGAAGTGGCGTGAGAAAT for site 2 double-strand clone. They are centered at the SGp94S3 site level. a CCGGAAGTGGCATTGTTCCC for j es j te 3 BspEl restriction.
- DMEM Middle of Eagle modified by Dulbecco (Gibco BRL)
- MEM Non-essential amino acid solution (Gibco BRL)
- SVF Fetal calf serum (Gibco BRL)
- the DNA of the different plasmids is prepared according to the QIAGEN Endofree protocol
- Plasmids used pECFP-Nl (Clontech); pEYFP-Cl (Clontech).
- pTOMp The strategy of construction of the vector carrying the two sequences coding for ECFP and EYFP in phase (called pTOMp) consisted in digesting the plasmid pTOM by two restriction enzymes at unique sites on pTOM and generating blunt ends, Ec / 136II and Smal ( Figure 8). The linearized vector was purified and a ligation reaction of the vector on itself was carried out. After transformation and subculturing of positive colonies, a PCR reaction made it possible to confirm the presence of the plasmid in these colonies (FIG. 9). About a third of the transplanted colonies were thus able to be amplified and therefore had to contain the vector pTOMp.
- oligonucleotides coding for cleavage sites with calpain 3 in the expression vector pTOM To facilitate the phenomenon of FRET between the two proteins EYFP and ECFP, amino acids glycine and serine were added by hand and on the other side of the cleavage site so as to facilitate the bringing together of the two proteins, the glycines facilitating the flexibility of the chimeric protein and the serines increasing its solubility in an aqueous medium (FIG. 10).
- the sequence of the oligonucleotides is such that they form restriction sites for BspEl and BamBI at each end when they are paired.
- the bases marked in bold underlined in the sequences of the oligonucleotides are bases which do not modify the protein sequence but which are different from the genomic sequence. These bases have been modified in order to limit the formation of duplexes of homologous primers, which could hinder the formation of double-stranded oligonucleotides.
- the modification of the bases was also made according to the frequency of use of the codons in the mouse.
- the restriction sites used for cloning are unique sites.
- the enzyme BspEl is inactive if the cloning site is methylated.
- the cloning of the vector pTOM intended to receive the double-stranded oligonucleotides was therefore done in bacteria whose gene coding for Dam methylase is mutated.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02755089A EP1399545A2 (fr) | 2001-06-29 | 2002-06-24 | Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite mehtode |
US10/432,688 US20040180395A1 (en) | 2001-06-29 | 2002-06-24 | Method for detecting calpain3 activity in a biological sample and peptides for implementing said method |
AU2002321389A AU2002321389B2 (en) | 2001-06-29 | 2002-06-24 | Method for detecting calpain 3 activity in a biological sample and peptides for implementing said method |
CA002429429A CA2429429A1 (fr) | 2001-06-29 | 2002-06-24 | Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode |
JP2003509092A JP2004520850A (ja) | 2001-06-29 | 2002-06-24 | 生体試料のカルパイン3活性を検出する方法、および前記方法を実施するためのペプチド |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/08614 | 2001-06-29 | ||
FR0108614A FR2826656B1 (fr) | 2001-06-29 | 2001-06-29 | Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003002730A2 true WO2003002730A2 (fr) | 2003-01-09 |
WO2003002730A3 WO2003002730A3 (fr) | 2003-12-11 |
Family
ID=8864926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/002178 WO2003002730A2 (fr) | 2001-06-29 | 2002-06-24 | Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040180395A1 (fr) |
EP (1) | EP1399545A2 (fr) |
JP (1) | JP2004520850A (fr) |
CN (1) | CN1514878A (fr) |
AU (1) | AU2002321389B2 (fr) |
CA (1) | CA2429429A1 (fr) |
FR (1) | FR2826656B1 (fr) |
WO (1) | WO2003002730A2 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012517A2 (fr) * | 2003-07-28 | 2005-02-10 | Genethon | Utilisation du phenomene fret pour le suivi in vivo d'evenements biologiques |
JP2005040132A (ja) * | 2003-07-09 | 2005-02-17 | Japan Science & Technology Agency | 細胞内ip3測定用分子センサー |
FR2891544A1 (fr) * | 2005-09-30 | 2007-04-06 | Genethon Ass Loi De 1901 | Substrat proteique pour la detection de l'activite calpaine 3 |
WO2012001121A1 (fr) | 2010-07-01 | 2012-01-05 | Genethon | Inhibiteurs de la calpaïne 3 pour le traitement de dystrophies musculaires et de cardiomyopathies |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007049943A (ja) * | 2005-08-18 | 2007-03-01 | Kyoto Univ | 細胞内カルシウムイオン指示機能を有するポリペプチド |
CN102154288B (zh) * | 2010-12-21 | 2012-12-19 | 山东农业大学 | 一种骨骼肌特异性capn3启动子及其应用 |
WO2014136780A1 (fr) * | 2013-03-04 | 2014-09-12 | 国立大学法人 東京大学 | Sonde fluorescente pour la détection de l'activité de la calpaïne |
CN104655596A (zh) * | 2013-11-18 | 2015-05-27 | 李捷 | 一种含红细胞血液样品的质量检测方法及检测试剂盒 |
EP3987050A1 (fr) * | 2019-06-24 | 2022-04-27 | Urteste S.A. | Nouveau marqueur de diagnostic pour le cancer du pancréas |
AU2022297106A1 (en) * | 2021-06-24 | 2023-12-07 | Goryo Chemical, Inc. | Fluorescent probes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19650142A1 (de) * | 1996-12-04 | 1998-06-10 | Basf Ag | Neue Calpaine, ihre Herstellung und Verwendung |
-
2001
- 2001-06-29 FR FR0108614A patent/FR2826656B1/fr not_active Expired - Fee Related
-
2002
- 2002-06-24 AU AU2002321389A patent/AU2002321389B2/en not_active Ceased
- 2002-06-24 JP JP2003509092A patent/JP2004520850A/ja active Pending
- 2002-06-24 CA CA002429429A patent/CA2429429A1/fr not_active Abandoned
- 2002-06-24 CN CNA028057309A patent/CN1514878A/zh active Pending
- 2002-06-24 WO PCT/FR2002/002178 patent/WO2003002730A2/fr not_active Application Discontinuation
- 2002-06-24 EP EP02755089A patent/EP1399545A2/fr not_active Withdrawn
- 2002-06-24 US US10/432,688 patent/US20040180395A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19650142A1 (de) * | 1996-12-04 | 1998-06-10 | Basf Ag | Neue Calpaine, ihre Herstellung und Verwendung |
Non-Patent Citations (4)
Title |
---|
KINBARA K ET AL: "Purification of native p94, a muscle-specific calpain, and characterization of its autolysis." THE BIOCHEMICAL JOURNAL. ENGLAND 1 NOV 1998, vol. 335 ( Pt 3), 1 novembre 1998 (1998-11-01), pages 589-596, XP002238589 ISSN: 0264-6021 * |
ONO Y ET AL: "Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 3 JUL 1998, vol. 273, no. 27, 3 juillet 1998 (1998-07-03), pages 17073-17078, XP002238594 ISSN: 0021-9258 * |
See also references of EP1399545A2 * |
VANDERKLISH PETER W ET AL: "Marking synaptic activity in dendritic spines with a calpain substrate exhibiting fluorescence resonance energy transfer." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 5, 29 février 2000 (2000-02-29), pages 2253-2258, XP002194684 Feb. 29, 2000 ISSN: 0027-8424 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005040132A (ja) * | 2003-07-09 | 2005-02-17 | Japan Science & Technology Agency | 細胞内ip3測定用分子センサー |
WO2005012517A2 (fr) * | 2003-07-28 | 2005-02-10 | Genethon | Utilisation du phenomene fret pour le suivi in vivo d'evenements biologiques |
WO2005012517A3 (fr) * | 2003-07-28 | 2005-04-21 | Genethon | Utilisation du phenomene fret pour le suivi in vivo d'evenements biologiques |
FR2891544A1 (fr) * | 2005-09-30 | 2007-04-06 | Genethon Ass Loi De 1901 | Substrat proteique pour la detection de l'activite calpaine 3 |
WO2007039699A2 (fr) * | 2005-09-30 | 2007-04-12 | Genethon | Substrat proteique pour la detection de l'activite calpaine 3 |
WO2007039699A3 (fr) * | 2005-09-30 | 2007-05-24 | Genethon | Substrat proteique pour la detection de l'activite calpaine 3 |
WO2012001121A1 (fr) | 2010-07-01 | 2012-01-05 | Genethon | Inhibiteurs de la calpaïne 3 pour le traitement de dystrophies musculaires et de cardiomyopathies |
Also Published As
Publication number | Publication date |
---|---|
EP1399545A2 (fr) | 2004-03-24 |
FR2826656A1 (fr) | 2003-01-03 |
CA2429429A1 (fr) | 2003-01-09 |
AU2002321389B2 (en) | 2005-03-24 |
JP2004520850A (ja) | 2004-07-15 |
FR2826656B1 (fr) | 2003-09-12 |
US20040180395A1 (en) | 2004-09-16 |
CN1514878A (zh) | 2004-07-21 |
WO2003002730A3 (fr) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Herman et al. | Lack of a robust unfoldase activity confers a unique level of substrate specificity to the universal AAA protease FtsH | |
Suzuki et al. | Calpain: novel family members, activation, and physiological function | |
Shimada et al. | Alanine scanning mutagenesis of the switch I region in the ATPase site of Dictyostelium discoideum myosin II | |
WO2003002730A2 (fr) | Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode | |
Ma et al. | Mechanism of dephosphorylation of the SR protein ASF/SF2 by protein phosphatase 1 | |
Unsworth et al. | Dynamin is required for F‐actin assembly and pedestal formation by enteropathogenic Escherichia coli (EPEC) | |
Mannan et al. | An Ire1–Phk1 Chimera Reveals a Dispensable Role of Autokinase Activity in Endoplasmic Reticulum Stress Response | |
Elgert et al. | A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC | |
Averna et al. | Changes in calpastatin localization and expression during calpain activation: a new mechanism for the regulation of intracellular Ca 2+-dependent proteolysis | |
Peng et al. | Vesicle encapsulation stabilizes intermolecular association and structure formation of functional RNA and DNA | |
Chen et al. | Designing protease sensors for real-time imaging of trypsin activation in pancreatic cancer cells | |
Ketteler et al. | A pathway sensor for genome-wide screens of intracellular proteolytic cleavage | |
Leonard et al. | Analysis of dishevelled localization and function in the early sea urchin embryo | |
WO2007039699A2 (fr) | Substrat proteique pour la detection de l'activite calpaine 3 | |
Baba et al. | Effects of neutral salts and pH on the activity and stability of human RNase H2 | |
US7982021B2 (en) | Nucleic acid molecules encoding emission ratiometric indicators of phosphoinositides | |
EP1442298B1 (fr) | Procede de selection d'agents bio-actifs par couplage de luminescence et systeme cellulaire vivant pour la mise en oeuvre de ce procede | |
Grabau et al. | Lipid binding by Escherichia coli pyruvate oxidase is disrupted by small alterations of the carboxyl-terminal region | |
Thompson et al. | A conserved tyrosine residue of Saccharomyces cerevisiae leukotriene A4 hydrolase stabilizes the transition state of the peptidase activity | |
Xiao et al. | Roles of μ-calpain in cultured L8 muscle cells: application of a skeletal muscle-specific gene expression system | |
EP1171601B1 (fr) | Acides nucleiques codant un polypeptide comprenant un domaine mutt | |
CA2659353C (fr) | Composition et procede pour le traitement de tumeurs | |
TWI457565B (zh) | 用於鑑別出改變NAPE-PLD或Abh4之作用劑的分析方法 | |
Parchaliuk et al. | Yeast two-hybrid system | |
WO2005012913A2 (fr) | Procede de mise en evidence d'un evenement moleculaire dans une cellule grace a des proteines marqueurs fluorescentes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002321389 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002755089 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2429429 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10432688 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003509092 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028057309 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002755089 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004110229 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002321389 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002755089 Country of ref document: EP |